SAB Biotherapeutics (SABS) Stock Forecast & Price Target

Compare

185 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SABS Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

SAB

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SABS Stock 12 Month Forecast

Average Price Target

$12.00

▲(212.50% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for SAB Biotherapeutics in the last 3 months. The average price target is $12.00 with a high forecast of $15.00 and a low forecast of $9.00. The average price target represents a 212.50% change from the last price of $3.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.79,4.6523076923076925,5.514615384615385,6.376923076923077,7.239230769230769,8.10153846153846,8.963846153846154,9.826153846153847,10.688461538461539,11.55076923076923,12.413076923076922,13.275384615384617,14.137692307692308,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.79,4.421538461538462,5.053076923076923,5.684615384615385,6.3161538461538465,6.947692307692308,7.57923076923077,8.21076923076923,8.842307692307692,9.473846153846154,10.105384615384615,10.736923076923077,11.368461538461538,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.79,4.190769230769231,4.591538461538462,4.992307692307692,5.393076923076923,5.793846153846154,6.194615384615385,6.595384615384615,6.996153846153846,7.396923076923077,7.797692307692308,8.198461538461538,8.599230769230768,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$15.00

Average Price Target$12.00

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yatin Suneja

Guggenheim

$15

Buy

290.63%

Upside

Initiated

12/19/25

SAB Biotherapeutics initiated with a Buy at GuggenheimSAB Biotherapeutics initiated with a Buy at Guggenheim

Emily Bodnar

H.C. Wainwright

Buy

134.38%

Upside

Reiterated

12/17/25

SAB Biotherapeutics: Favorable SAB-142 Safety Profile and De-Risked Phase 2b Design Underpin Buy Rating

Thomas Smith

Leerink Partners

Buy

―

Reiterated

10/21/25

SAB Biotherapeutics (SABS) Receives a Rating Update from a Top Analyst

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

Buy

82.29%

Upside

Initiated

09/17/25

SAB Biotherapeutics (SABS) Receives a New Rating from Roth MKM

Albert Lowe

Craig-Hallum

Buy

30.21%

Upside

Reiterated

08/11/25

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

Keay Nakae

Chardan Capital

$20→$12

Buy

212.50%

Upside

Reiterated

08/08/25

SAB Biotherapeutics price target lowered to $12 from $20 at ChardanSAB Biotherapeutics price target lowered to $12 from $20 at Chardan

Leland Gershell

Oppenheimer

$12→$14

Buy

264.58%

Upside

Reiterated

07/21/25

Oppenheimer Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yatin Suneja

Guggenheim

$15

Buy

290.63%

Upside

Initiated

12/19/25

SAB Biotherapeutics initiated with a Buy at GuggenheimSAB Biotherapeutics initiated with a Buy at Guggenheim

Emily Bodnar

H.C. Wainwright

Buy

134.38%

Upside

Reiterated

12/17/25

SAB Biotherapeutics: Favorable SAB-142 Safety Profile and De-Risked Phase 2b Design Underpin Buy Rating

Thomas Smith

Leerink Partners

Buy

―

Reiterated

10/21/25

SAB Biotherapeutics (SABS) Receives a Rating Update from a Top Analyst

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

Buy

82.29%

Upside

Initiated

09/17/25

SAB Biotherapeutics (SABS) Receives a New Rating from Roth MKM

Albert Lowe

Craig-Hallum

Buy

30.21%

Upside

Reiterated

08/11/25

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

Keay Nakae

Chardan Capital

$20→$12

Buy

212.50%

Upside

Reiterated

08/08/25

SAB Biotherapeutics price target lowered to $12 from $20 at ChardanSAB Biotherapeutics price target lowered to $12 from $20 at Chardan

Leland Gershell

Oppenheimer

$12→$14

Buy

264.58%

Upside

Reiterated

07/21/25

Oppenheimer Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering SAB Biotherapeutics

1 Month

xxx

Success Rate

4/6 ratings generated profit

Average Return

+2.63%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.63% per trade.

3 Months

xxx

Success Rate

6/6 ratings generated profit

Average Return

+27.30%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +27.30% per trade.

1 Year

Emily BodnarH.C. Wainwright

Success Rate

6/6 ratings generated profit

Average Return

+55.57%

reiterated a buy rating 7 days ago

Copying Emily Bodnar's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +55.57% per trade.

2 Years

xxx

Success Rate

5/5 ratings generated profit

Average Return

+86.26%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +86.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SABS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SABS has received 6 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. SABS average Analyst price target in the past 3 months is 12.00.

Each month's total comprises the sum of three months' worth of ratings.

SABS Financial Forecast

SABS Earnings Forecast

Next quarter’s earnings estimate for SABS is -$0.20 with a range of -$0.28 to -$0.15. The previous quarter’s EPS was -$0.21. SABS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SABS has Performed in-line its overall industry.

SABS Sales Forecast

Next quarter’s sales forecast for SABS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SABS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SABS has Performed in-line its overall industry.

SABS Stock Forecast FAQ

What is SABS’s average 12-month price target, according to analysts?

Based on analyst ratings, SAB Biotherapeutics’s 12-month average price target is 12.00.

What is SABS’s upside potential, based on the analysts’ average price target?

SAB Biotherapeutics has 212.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SABS a Buy, Sell or Hold?

SAB Biotherapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is SAB Biotherapeutics’s price target?

The average price target for SAB Biotherapeutics is 12.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $9.00. The average price target represents 212.50% Increase from the current price of $3.84.

What do analysts say about SAB Biotherapeutics?

SAB Biotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of SABS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

SAB Biotherapeutics (SABS) Stock Forecast & Price Target

SABS Analyst Ratings

SABS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering SAB Biotherapeutics

SABS Analyst Recommendation Trends

SABS Financial Forecast

SABS Earnings Forecast

SABS Sales Forecast

SABS Stock Forecast FAQ

Detailed List of Analyst Forecasts